Free Newsletter
Roche stalls; Genentech soldiers on
Free newsletter via e-mail
Tools
A Genentech official tells the WSJ Health Blog that the company's morale hasn't been affected by the still-treading-water Roche buyout. Nor have employees begun to head for the doors. But In the Pipeline is skeptical, both of the supposed unchanged morale and of the eventual deal itself. Report | Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
